(2-异丙基苯氧基)-乙酸 | 25141-58-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-异丙基苯氧基)-乙酸
• 中文别名: (2-异丙基-苯氧基)-乙酸
• 英文名称: 2-(2-isopropylphenoxy)acetic acid
• 英文别名: <2-Isopropyl-phenoxy>-essigsaeure；(2-isopropylphenoxy)acetic acid；2-(2-propan-2-ylphenoxy)acetic acid
• CAS: 25141-58-6
• 化学式: C₁₁H₁₄O₃
• mdl: MFCD00463165
• 分子量: 194.23
• InChiKey: HGGPCQVBKJMWHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  室温

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : (2-Isopropylphenoxy)Acetic Acid
: OTV000134
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 194,23 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
(2-Isopropylphenoxy)Acetic Acid
Acute Tox. 4; Eye Irrit. 2; <= 100 %
H302, H319
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
(2-Isopropylphenoxy)Acetic Acid
Xn, R22R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
R22 Harmful if swallowed.
R36 Irritating to eyes.
Further information
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2-异丙基苯氧基)-乙酸 在 2,6-二甲基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-(2-isopropylphenoxy)-N-(2-(2-(2-methoxyphenoxy)acetamido)phenyl)acetamide
  参考文献：
  名称：

  Modulation of DNA damage response by targeting ATM kinase using newly synthesized di-phenoxy acetamide (DPA) analogs to induce anti-neoplasia

  摘要：

  DNA结构的失衡和不稳定性已成为癌症的主要特征。在应对DNA损伤时，DNA损伤反应（DDR）蛋白，共济失调毛细血管扩张突变（ATM）在调节负责抑制凋亡的调控区域中发挥着关键作用，从而促进肿瘤进展。合成了一系列新的DPA（7a–t）并进行了特征化。通过LDH和MTT assay进行抗增殖研究以鉴定先导化合物。通过FACS、 Annexin-v染色、TUNEL和Comet assay测量凋亡/DNA损伤。通过免疫印迹阐明分子机制，并通过体内方法进一步验证药物效果。对化合物DPA（7a–t）进行的初步体外抗增殖筛选针对多种癌细胞系，鉴定出化合物DPA（7n）为一种强效细胞毒性分子，其IC50值为4.3μM。通过化合物DPA（7n）的体外和体内评估推断其具有诱发凋亡的潜力。进一步评估分子机制推断化合物DPA（7n）仅有效地调节ATM磷酸化，最终改变下游信号传导途径。化合物DPA（7n）在体外和体内抑制ATM激酶活性，展现出强大的促凋亡和抗肿瘤特性。这些结果确认该药物可能被开发为具有抗癌能力的新型ATM激酶抑制剂。

  DOI：

  10.1007/s43440-021-00292-6
• 作为产物：
  描述：

  异丙苯酚 在 potassium carbonate 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 丙酮 为溶剂， 生成 (2-异丙基苯氧基)-乙酸
  参考文献：
  名称：

  Modulation of DNA damage response by targeting ATM kinase using newly synthesized di-phenoxy acetamide (DPA) analogs to induce anti-neoplasia

  摘要：

  DNA结构的失衡和不稳定性已成为癌症的主要特征。在应对DNA损伤时，DNA损伤反应（DDR）蛋白，共济失调毛细血管扩张突变（ATM）在调节负责抑制凋亡的调控区域中发挥着关键作用，从而促进肿瘤进展。合成了一系列新的DPA（7a–t）并进行了特征化。通过LDH和MTT assay进行抗增殖研究以鉴定先导化合物。通过FACS、 Annexin-v染色、TUNEL和Comet assay测量凋亡/DNA损伤。通过免疫印迹阐明分子机制，并通过体内方法进一步验证药物效果。对化合物DPA（7a–t）进行的初步体外抗增殖筛选针对多种癌细胞系，鉴定出化合物DPA（7n）为一种强效细胞毒性分子，其IC50值为4.3μM。通过化合物DPA（7n）的体外和体内评估推断其具有诱发凋亡的潜力。进一步评估分子机制推断化合物DPA（7n）仅有效地调节ATM磷酸化，最终改变下游信号传导途径。化合物DPA（7n）在体外和体内抑制ATM激酶活性，展现出强大的促凋亡和抗肿瘤特性。这些结果确认该药物可能被开发为具有抗癌能力的新型ATM激酶抑制剂。

  DOI：

  10.1007/s43440-021-00292-6

文献信息

• Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
  申请人：——

  公开号：US20040072838A1

  公开（公告）日：2004-04-15

  The present invention provides a compound of formula (1) wherein R 1 -R 5 , R 25 , R 26 , Y and X 2 are defined as in claim 1. The compounds activate human peroxisome proliferator activated receptors (hPPARs) and arc useful for the treatment of associated disorders such as cardiovascular disease and hypercholesteremia. 1

  本发明提供了一种化合物，其化学式为（1），其中R1-R5，R25，R26，Y和X2的定义如权利要求1中所述。这些化合物能激活人类过氧化物酶体增殖物激活受体（hPPARs），并且对于治疗相关疾病如心血管疾病和高胆固醇血症非常有用。
• [EN] 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-((HÉTÉRO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DÉCANE
  申请人：GRUENENTHAL GMBH

  公开号：WO2017121647A1

  公开（公告）日：2017-07-20

  The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

  本发明涉及3-（杂）芳基-8-氨基-2-氧代-1,3-二氮杂螺[4.5]癸烷衍生物，它们的制备方法以及它们在医药中的应用，特别是在治疗疼痛方面的应用。
• CCR2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Basak Arindrajit

  公开号：US20100234364A1

  公开（公告）日：2010-09-16

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR2或CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，在制药组合物、治疗CCR2介导疾病的方法、治疗CCR9介导疾病的方法、作为CCR2拮抗剂鉴定的检测中的对照物，以及作为CCR9拮抗剂鉴定的检测中的对照物中非常有用。
• Targeting HIF-1α by newly synthesized Indolephenoxyacetamide (IPA) analogs to induce anti-angiogenesis-mediated solid tumor suppression
  作者：Fares Hezam Al-Ostoot、Ankith Sherapura、Vigneshwaran V、Giridhara Basappa、Vivek H.K.、Prabhakar B.T、Shaukath Ara Khanum

  DOI：10.1007/s43440-021-00266-8

  日期：2021.10

  Hypoxic microenvironment is a common feature of solid tumors, which leads to the promotion of cancer. The transcription factor, HIF-1α, expressed under hypoxic conditions stimulates tumor angiogenesis, favoring HIF-1α as a promising anticancer agent. On the other hand, synthetic Indolephenoxyacetamide derivatives are known for their pharmacological potentiality. With this background here, we have synthesized, characterized, and validated the new IPA (8a–n) analogs for anti-tumor activity. The new series of IPA (8a–n) were synthesized through a multi-step reaction sequence and characterized based on the different spectroscopic analysis FT-IR, 1H, 13C NMR, mass spectra, and elemental analyses. Cell-based screening of IPA (8a–n) was assessed by MTT assay. Anti-angiogenic efficacy of IPA (8k) validated through CAM, Rat corneal, tube formation and migration assay. The underlying molecular mechanism is validated through zymogram and IB studies. The in vivo anti-tumor activity was measured in the DLA solid tumor model. Screening for anti-proliferative studies inferred, IPA (8k) is a lead molecule with an IC50 value of ˜5 μM. Anti-angiogenic assays revealed the angiopreventive activity through inhibition of HIF-1α and modulation downstream regulatory genes, VEGF, MMPs, and P53. The results are confirmative in an in vivo solid tumor model. The IPA (8k) is a potent anti-proliferative molecule with anti-angiogenic activity and specifically targets HIF1α, thereby modulates its downstream regulatory genes both in vitro and in vivo. The study provides scope for new target-specific drug development against HIF-1α for the treatment of solid tumors.

  低氧微环境是实体瘤的常见特征，它促进了癌症的发展。在低氧条件下表达的转录因子HIF-1α刺激肿瘤血管生成，使HIF-1α成为一个有前景的抗癌剂。另一方面，合成吲哚酚氧乙酰胺衍生物以其药理潜力而闻名。基于此背景，我们合成了新型IPA（8a-n）类似物，并验证了其抗肿瘤活性。新系列的IPA（8a-n）通过多步骤反应序列合成，并基于不同的光谱分析FT-IR、1H、13C NMR、质谱和元素分析进行表征。通过MTT assay评估了IPA（8a-n）的基于细胞的筛选。通过CAM、大鼠角膜、管形成和迁移实验验证了IPA（8k）的抗血管生成效果。通过酶谱和IB研究验证了其分子机制。在DLA实体瘤模型中测量了体内抗肿瘤活性。进行抗增殖研究筛选，结果显示IPA（8k）是一个领先分子，其IC50值约为5μM。抗血管生成实验揭示了通过抑制HIF-1α和调节下游调节基因VEGF、MMPs和P53来预防血管生成的活性。在体内实体瘤模型中得到了确认的结果。IPA（8k）是一个强效的抗增殖分子，具有抗血管生成活性，并特异性地靶向HIF1α，从而调节其下游调节基因在体外和体内。该研究为针对HIF-1α的针对特定靶点的新药开发提供了范围，用于治疗实体瘤。
• The Effects of Growth Hormone Replacement Therapy on Bone Metabolism in Adult-Onset Growth Hormone Deficiency: A 2-Year Open Randomized Controlled Multicenter Trial
  作者：Marie Bex、Roger Abs、Dominique Maiter、Albert Beckers、Gerard Lamberigts、Roger Bouillon

  DOI：10.1359/jbmr.2002.17.6.1081

  日期：——

  Adult hypopituitary patients with growth hormone deficiency (GHD) show a significant decrease in bone mass and an increased fracture rate. Replacement therapy with GH increases bone turnover. Most of the long‐term data on bone mineral content (BMC) and bone mineral density (BMD) have been acquired in open, noncontrolled trials involving limited numbers of patients. To determine whether long‐term GH therapy is beneficial for bone despite the increased bone turnover, 100 patients (59 men and 41 women), aged 25‐65 years (mean, 49.7 years) with adult‐onset GHD were randomized to treatment with GH (40 men and 28 women; mean dose, 0.18 IU/kg per week) or to a nontreated control group (19 men and 13 women) for 24 months. Despite a similar increase in parameters of bone turnover (osteocalcin [OC], procollagen type I carboxy‐terminal propeptide [PICP], and pyridinolines ([PYD]) in male and female GH‐treated patients compared with controls, the effects on BMC and BMD as evaluated by dual‐energy X‐ray absorptiometry were gender specific. A significant increase in spine BMC and BMD and total hip BMD and a decrease in BMD at the ultradistal radius over time was observed in male GH‐treated patients compared with the evolution in controls (mean ± SEM change at 24 months: +6.8 ± 1.1% and p = 0.009, +5.1 ± 0.8% and p = 0.005, +3.5 ± 0.7% and p = 0.02, and −2.6 ± 0.8% and p = 0.008, respectively). No significant treatment effects were observed in female patients. Despite the increase in the total remodeling space induced by GH treatment, prolonged GH therapy in adult‐onset GHD has a positive effect on bone balance, maintaining bone mass in women, and even increasing it in men over a 2 year‐period.

  成人生长激素缺乏症（GHD）患者表现出骨量显著减少和骨折率增加。生长激素（GH）替代治疗能够增加骨代谢率。关于骨矿含量（BMC）和骨密度（BMD）的长期数据主要来自于开放式的非对照试验，涉及患者人数有限。为了确定尽管骨代谢率增加但长期GH治疗是否对骨骼有益，研究将100名（59名男性和41名女性），年龄介于25至65岁（平均年龄49.7岁）且具有成年起病GHD的患者随机分配至GH治疗组（40名男性和28名女性；平均剂量为0.18 IU/kg每周）或未治疗对照组（19名男性和13名女性），持续24个月。尽管GH治疗组男性和女性患者的骨代谢参数（骨钙素[OC]，I型前胶原羧端前肽[PICP]，和吡啶醇[PYD]）与对照组相比均有类似的增加，但通过双能X射线吸收测定法评估的BMC和BMD的效果在性别上有所差异。与对照组的变化相比，男性GH治疗组患者的脊柱BMC和BMD及总髋BMD显著增加，超远端桡骨BMD则有所减少（24个月的平均±标准误变化：+6.8 ± 1.1%，p = 0.009；+5.1 ± 0.8%，p = 0.005；+3.5 ± 0.7%，p = 0.02；和−2.6 ± 0.8%，p = 0.008）。在女性患者中未观察到显著的治疗效果。尽管GH治疗导致总重塑空间增加，成年起病GHD的长期GH治疗对骨平衡有积极影响，在两年内能够维持女性的骨量，甚至在男性中增加骨量。